

FORM PTO-1449 (Modified)

FEB 11 1999

Attorney Docket No.: 018623-005890US

Application No.: 09/017,735

LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENT (Use several sheets if necessary)

Applicant: Howard M. Grey et al.

Filing Date: 2/3/98

Group: 1642

Reference Designation

U.S. PATENT DOCUMENTS

Page 1



Examiner Initial	Document No.	Date	Name	Class	Sub-class	Filing Date (If Appropriate)
<u>M</u> A1	5,342,774	08/30/94	Boon <i>et al.</i>	435	240.2	12/12/91
<u>I</u> A2	5,200,320	04/06/93	Sette <i>et al.</i>	435	7.24	12/07/87
<u>V</u> A3	5,405,940	04/11/95	Boon <i>et al.</i>	530	328	08/31/92

FOREIGN PATENT DOCUMENTS

	Document No.	Date	Country	Class	Sub-class	Translation (Yes/No)
<u>C</u> B1	WO 94/05304 (PCT/US93/08157)	03/17/94	PCT WO	G07K	7/06	
<u>M</u> B2	WO 92/21033	11/92	PCT WO	—	—	yes NO
<u>M</u> B3	WO 94/11738	5/94	PCT WO	—	—	NO
<u>P</u> B4	WO 92/02543	2/92	PCT WO	—	—	
<u>B</u> B5	WO 95/25122	9/21/95	PCT WO	G07K	14/18	
<u>M</u> B6	WO 94/20127	9/15/94	PCT WO	A61K	37/02	

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

<u>M</u> C1	Celis, E. et al., Proc. Natl. Acad. Sci. USA 91: 2105-2109 (March, 1994), "Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes"
<u>P</u> C2	Ding, M. et al., Biochem. Biophys. Res. Commun. 202(1): 549-555 (July 15, 1994), "Cloning and analysis of MAGE-1-related genes"
<u>M</u> C3	Gaugler, B. et al., J. Exp. Med. 179(3): 921-930 (March 1, 1994), "Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes"
<u>M</u> C4	Oaks, M.K. et al., Cancer Res. 54: 1627-1629 (April 1, 1994), "Molecular cytogenetic mapping of the human melanoma antigen (MAGE) gene family to chromosome region Xq27-qtr: implications for MAGE immunotherapy"
<u>P</u> C5	Paul, W.F.(ed.), Fundamental Immunology, 3rd ed., pp. 976-978 (1993), Raven Press, NY
<u>M</u> C6	Traversari, C. et al., J. Exp. Med. 176: 1453-1457 (November, 1992), "A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E"
<u>P</u> C7	Robbins Pathologic Basis of Disease, 4 th edition (R.S. Cotran et. al., ed.), pp. 296-299 (1989), W.B. Saunders Co., Philadelphia
<u>B</u> C8	Weynants, P. et al., Int. J. Cancer, 56: 826-829 (1994), "Expression of MAGE genes by non-small-cell lung carcinomas"
<u>M</u> C9	Zakut, R. et al., Cancer Res. 53: 5-8 (January 1, 1993), "Differential expression of MAGE-1, -2, and -3 messenger RNA in transformed and normal human cell lines"
<u>M</u> C10	Urban, J.L., et al., "Autoimmune T Cells: Immune Recognition of Normal and Variant Peptide Epitopes and Peptide-Based Therapy," Cell 59:257-271 (October 20, 1989).
<u>P</u> C11	Wraith, D.C., et al., "Antigen Recognition in Autoimmune Encephalomyelitis and the Potential for Peptide-Mediated Immunotherapy," Cell 59:247-255 (October 20, 1989).
<u>M</u> C12	Parker, K.C., et al., "Peptide Binding to HLA-A2 and HLA-B27 Isolated from <i>Escherichia coli</i> " J. Biol. Chem. 267(8):5451-5459 (March 15, 1992).

FEB 11 1998
PATENT & TRADEMARK OFFICE

FORM PTO-1449 (Modified)		Attorney Docket No.: 018623-005890US	Application No.: 09/017,735
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Howard M. Grey et al.	
		Filing Date: 2/3/98	Group: 1642
✓ C13	Morrison, J., et al., "Identification of the nonamer peptide from influenza A matrix protein and the role of pockets of HLA-A2 in its recognition by cytotoxic T lymphocytes," <i>Eur. J. Immunol.</i> , 22:903-907 (1992).		
✓ C14	Shimojo, N., et al., "Specificity of Peptide Binding by the HLA-A2.1 Molecule," <i>J. of Immunol.</i> 143(9):2939-2947 (November 1, 1989).		
✓ C15	Carreno, B.M., et al., "HLA-B37 and HLA-A2.1 molecules bind largely nonoverlapping sets of peptides," <i>Proc. Natl. Acad. Sci. USA</i> , 87:3420-3424 (May 1990).		
✓ C16	Henderson, R.A., et al., "HLA-A2.1-Associated Peptides from a Mutant Cell Line: A Second Pathway of Antigen Presentation," <i>Science</i> 255:1264-1266 (10 February 1992).		
+ C17	Kannagi, M., et al., "Target Epitope in the Tax Protein of Human T-Cell Leukemia Virus Type I Recognized by Class I Major Histocompatibility Complex-Restricted Cytotoxic T Cells," <i>J. of Virol.</i> 66 (5) :2928-2933 (May 1992).		
✓ C18	Falk, K., et al., "Allele-specific motifs revealed by sequencing of self-peptide eluted from MHC molecules," <i>Nature</i> 351:290-296 (23 May 1991).		
✓ C19	Jardetzky, T.S., et al., "Identification of self peptides bound to purified HLA-B27," <i>Nature</i> 353:326-329 (September 26, 1991).		
✓ C20	Hunt, D.F., et al., "Characterization of Peptides Bound to the Class I MHC Molecule HLA-A2.1 by Mass Spectrometry," <i>Science</i> 255:1261-1263 (March 6, 1992).		
✓ C21	Rotzschke, O., et al., "Naturally occurring peptide antigens derived from the MHC class-I-restricted processing pathway," <i>Immunology Today</i> 12(12):447-455 (1991).		
✓ C22	De Bruijn, M.L.H., et al., "Peptide loading of empty major histocompatibility complex molecules on RMA-S cells allows the induction of primary cytotoxic T lymphocyte responses," <i>Eur. J. Immunol.</i> 21:2963-2970 (1991).		
✓ C23	Pamer, E.G., et al., "Precise prediction of a dominant class I MHC-restricted epitope of <i>Listeria monocytogenes</i> ," <i>Nature</i> 353:852-855 (October 31, 1991).		
✓ C24	DiBrino, M., et al., "Endogenous peptides bound to HLA-A3 possess a specific combination of anchor residues that permit identification of potential antigenic peptides," <i>Proc. Nat'l. Acad. Sci. USA</i> 90: 1508-1512 (February 1993).		
✓ C25	Paul, W.F. (ed.), <i>Fundamental Immunology</i> , 2nd ed., pp. 473-487 (1989), Raven Press, NY		
✓ C26	Romero et al., <i>J. Exp. Med.</i> 174: 603-612 (Sept. 1991), "H-2Kd-restricted antigenic peptides share a simple binding motif".		
✓ C27	Sette et al., <i>Proc. Nat'l. Acad. Sci. USA</i> 86: 3296-3300 (1989), "Prediction of major histocompatibility complex binding regions by sequence pattern analysis".		
✓ C28	Krieger et al., <i>J. Immunol.</i> 146: 2331-2340 (1991) "Single amino acid changes in DR and antigen define residues critical for peptide-MHC binding and T cell recognition".		
✓ C29	Sette et al., <i>J. Immunol.</i> 147: 3893-3900 (1991), "Random association between the peptide repertoire of A2.1 Class I and several different DR Class II molecules".		
✓ C30	Knuth et al., <i>Curr. Opinion Immunol.</i> (1991) 3: 659-664, "Cellular and humoral immune responses against cancer: implications for cancer vaccines".		
✓ C31	Viret et al., <i>Eur. J. Immunol.</i> (1993) 23: 141-146, "Recognition of shared melanoma antigen by HLA-A2-restricted cytolytic T cell clones derived from human tumor-infiltrating lymphocytes".		
✓ C32	Hayashi et al., <i>J. Immunol.</i> (1992) 149: 1223-1229, "Molecular cloning and characterization of the gene encoding mouse melanoma antigen by cDNA library transfection".		
✓ C33	Storkus et al., <i>J. Immunol.</i> (Oct. 1, 1993) 151: 3719-3727, "Identification of human melanoma peptides recognized by Class I restricted tumor infiltrating T lymphocytes".		

[Signature]


7/11/2001

FEB 11 1999



FORM PTO-1449 (Modified)		Attorney Docket No.: 018623-005890US	Application No.: 09/017,735
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Howard M. Grey et al.	
		Filing Date: 2/3/98	Group: 1642
<input checked="" type="checkbox"/> C34	Slingluff <i>et al.</i> , <i>J. Immunol.</i> (April 1, 1993) 150: 2955-2960, "Recognition of human melanoma cells by HLA-A2.1-restricted cytotoxic T lymphocytes is mediated by at least six shared peptide epitopes".		
<input type="checkbox"/> C35	Van der Bruggen <i>et al.</i> , <i>Science</i> (Dec. 13, 1991) 254: 1643-1647, "A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma".		
<input type="checkbox"/> C36	Maryanski <i>et al.</i> , <i>Cell</i> 60: 63-72 (1990) "Competitor analogs for defined T cell antigens: peptides incorporating a putative binding motif and polyproline or polyglycine spacers".		
<input checked="" type="checkbox"/> C37	Bjorkman <i>et al.</i> , "Structure of the human class I histocompatibility antigen HLA-A2," <i>Nature</i> (1987) 329: 506		
<input type="checkbox"/> C38	Buus <i>et al.</i> , <i>Science</i> (1988) 242: 1045-1047 "Autologous peptides constitutively occupy the antigen binding site on Ia"		
<input type="checkbox"/> C39	Celis <i>et al.</i> , <i>Mol. Immunol.</i> (1994) 31: 1423-1430, "Identification of potential CTL epitopes of tumor-associated antigen MAGE-1 for five common HLA-A alleles"		
<input checked="" type="checkbox"/> C40	Rammensee <i>et al.</i> , <i>Immunogenet.</i> (1995) 41: 178-228, "MHC ligands and peptide motifs: first listing"		
<input checked="" type="checkbox"/> C41	Rotzschke <i>et al.</i> , <i>Nature</i> (Nov. 15, 1990) 348: 252-254, "Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells"		
<input type="checkbox"/> C42	Rotzschke <i>et al.</i> , <i>Science</i> (July 20, 1990) 249: 283-287, "Characterization of naturally occurring minor histocompatibility peptides including H-4 and H-Y"		
<input type="checkbox"/> C43	Jiang <i>et al.</i> , <i>Science</i> (May 22, 1992) 256: 1213-1215, "Role of CD8* T cells in murine experimental allergic encephalomyelitis"		
<input type="checkbox"/> C44	Koh <i>et al.</i> , <i>Science</i> (May 22, 1992) 256: 1210-1213, "Less mortality but more relapses in experimental allergic encephalomyelitis in CDB ^{-/-} mice"		
<input type="checkbox"/> C45	Miller <i>et al.</i> , <i>Proc. Nat'l. Acad. Sci. USA</i> (January 1992) 89: 421-425, "Suppressor T cells generated by oral tolerization to myelin basic protein to suppress both <i>in vitro</i> and <i>in vivo</i> immune responses by the release of transforming growth factor β after antigen-specific triggering"		
<input type="checkbox"/> C46	Foon, <i>Cancer Res.</i> (April 1, 1989) 49: 1621-1639, "Biological response modifiers: the new immunotherapy"		
<input type="checkbox"/> C47	Parker <i>et al.</i> , <i>J. Immunol.</i> (December 1, 1992) 149:3580-3587, "Sequence motifs important for peptide binding to the human MHC Class I molecule, HLA-A2"		
<input type="checkbox"/> C48	Sarobe <i>et al.</i> , <i>Eur. J. Immunol.</i> (1991) 21:1555-1558 "Induction of antibodies against a peptide hapten does not require covalent linkage between the hapten and a class II presentable T helper peptide"		
<input type="checkbox"/> C49	Fynan <i>et al.</i> "DNA vaccines: Protective immunizations by parenteral, mucosal, and gene-gun inoculations," <i>Proc. Natl. Acad. Sci. USA</i> 90:11478-11482, December (1993)		
<input type="checkbox"/> C50	Battegay <i>et al.</i> "Patients with Chronic Hepatitis C Have Circulating Cytotoxic T Cells Which Recognize Hepatitis C Virus-Encoded Peptides Binding to HLA-A2.1 Molecules," <i>Journal of Virology</i> 2462-2470, April (1995)		
<input type="checkbox"/> C51	Rammensee <i>et al.</i> "Peptides Naturally Presented by MHC Class I Molecules," <i>Annu. Rev. Immunol.</i> 11:213-44 (1993)		
<input type="checkbox"/> C52	Cox <i>et al.</i> "Melanoma-Specific Human Cytotoxic T Cells Lines," <i>Science</i> 264:716-719, April (1994)		
<input type="checkbox"/> C53	Cerny <i>et al.</i> "Induction <i>in vitro</i> of a primary human antiviral cytotoxic T cell response," <i>Eur. J. Immunol.</i> 25:627-630, (1995)		
<input type="checkbox"/> C54	Wei <i>et al.</i> "HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides" <i>Nature</i> 356:443-446 (1992)		
<input checked="" type="checkbox"/> C55	Ochoa-Garay <i>et al.</i> "The ability of peptides to induce cytotoxic T cells <i>in vitro</i> does not strongly correlate with their affinity for the H-sLd molecule: implications for vaccine design and immunotherapy" <i>Molec. Immunol.</i> 34:273-281 (1997)		


2/11/2004



FORM PTO-1449 (Modified)		Attorney Docket No.: 018623-005890US	Application No.: 09/017,735
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Howard M. Gray et al.	
		Filing Date: 2/3/98	Group: 1642
<input checked="" type="checkbox"/> C56	Rudinger, J. "Characteristics of the amino acids as components of a peptide hormone sequence" in Peptide Hormones, edited by Parsons, J.A. University Park Press, 1976, pages 1-7		
<input type="checkbox"/> C57	Bruss, V. "A short linear sequence in the pre-S domain of the large hepatitis B virus envelope protein required for virion formation" J. Virol. 71:9350-9357 (December, 1997)		
<input type="checkbox"/> C58	Preisler-Adams, S. et al. "Complete nucleotide sequence of a hepatitis B virus, subtype adw2, and identification of three types of C open reading frames" Nucleic Acids Res. 21:2258 (1993)		
<input checked="" type="checkbox"/> C59	Engelhard, V. et al. "Structure of peptides associated with MHC Class I molecules" Curr. Opin. Immunol. 6:13-23 (1994)		
EXAMINER		DATE CONSIDERED 2/4/2007	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.





FORM PTO-1449 (Modified)		Attorney Docket No.: 18623-005890US		Application No.: 09/017,735		
LIST OF PATENTS AND PUBLICATIONS FOR REFERENCE		Applicant: Howard M. Grey et al.				
APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Filing Date: 2/3/98		Group: 1644		
Reference Designation		U.S. PATENT DOCUMENTS			Page 1	
Examiner Initial	Document No.	Date	Name	Class	Sub-class	Filing Date (If Appropriate)
___ AA						
___ AB						
___ AC						
___ AD						
___ AE						
___ AF						
___ AG						
___ AH						
___ AI						
___ AJ						
___ AK						
___ AL						
FOREIGN PATENT DOCUMENTS						
	Document No.	Date	Country	Class	Sub-class	Translation (Yes/No)
___ AM						
___ AN						
___ AO						
___ AP						
___ AQ						
___ AR						
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)						
127 AS	Rotzschke et al., "Peptide motifs of closely related HLA class I molecules encompass substantial differences" <i>Eur. J. Immunol.</i> 22:2453-2456 (1992)					
___ AT						
___ AU						
___ AV						
___ AW						
EXAMINER <u> </u> DATE CONSIDERED <u>7/11/2005</u>						

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.